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Abstract
Background: While, lost to follow-up (LTFU) from antiretroviral therapy (ART) can be considered a catch-all
category for patients who miss scheduled visits or medication pick-ups, operational definitions and methods for
defining LTFU vary making comparisons across programs challenging. Using weekly cut-offs, we sought to determine
the probability that an individual would return to clinic given that they had not yet returned in order to identify the
LTFU cut-off that could be used to inform clinical management and tracing procedures.
Methods: Individuals who initiated ART with Dignitas International supported sites (n = 22) in Zomba, Malawi between
January 1 2007-June 30 2010 and were≥ 1 week late for a follow-up visit were included. Lateness was categorized
using weekly cut-offs from ≥1 to ≥26 weeks late. At each weekly cut-off, the proportion of patients who returned for a
subsequent follow-up visit were identified. Cumulative Distribution Functions (CDFs) were plotted to determine the
probability of returning as a function of lateness. Hazard functions were plotted to demonstrate the proportion of
patients who returned each weekly interval relative to those who had yet to return.
Results: In total, n = 4484 patients with n = 7316 follow-up visits were included. The number of included
follow-up visits per patient ranged from 1–10 (median: 1). Both the CDF and hazard function demonstrated
that after being ≥9 weeks late, the proportion of new patients who returned relative to those who had yet to
return decreased substantially.
Conclusions: We identified a LTFU definition useful for clinical management. The simple functions plotted here
did not require advanced statistical expertise and were created using Microsoft Excel, making it a particularly
practical method for HIV programs in resource-constrained settings.
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Background
Operational definitions of Lost to Follow-up (LTFU)
from antiretroviral therapy (ART) vary widely across set-
tings, making comparisons across programs challenging
[1]. The development and identification of standardized
definitions of LTFU can inform cohort analyses [2, 3],
program evaluations [4] and tracing mechanisms. While
LTFU can be considered a general ‘catch-all’ category for
patients who miss scheduled clinic visits or medication
pick-ups [5], different definitions of LTFU within ART
programs can have a significant impact on LTFU esti-
mates over time [2, 4]. For example, in their 2013 study
Shepherd et al., reported that cumulative estimates of
LTFU varied widely, ranging from 22 % to 84 %; this
variation was primarily dependent on the definition of
LTFU that was applied [4]. This, in turn, has significant
implications for program planning purposes such as the
development of targeted strategies to improve retention.
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Current methods to assess LTFU rates have relied
largely on fixed time period cohort approaches, primarily
through the use of retrospective cohort analyses. Attri-
tion rates are often reported as proportions of patients
who meet a specific outcome at various time points
since ART initiation (e.g., 6 months, 12 months) [5–7],
although definitions of outcome measures over a speci-
fied period of follow-up are generally unclear [8]. Im-
portantly, there is no gold standard to measure retention
in care, and different measures (e.g., missed visits, fre-
quency of visits) have different advantages and limita-
tions [9–11]. Generally, when such information is
reported and available, patients who are known to have
died, stopped ART or transferred out are generally ex-
cluded in reported LTFU rates. In addition to a general
call for enhanced data on losses to follow-up [8], there
has also been a push toward developing more evidence-
based definitions [3, 12, 13] that minimize the misclassi-
fication of patients as LTFU. Related to this is the need
for LTFU definitions that can be used for clinical man-
agement purposes. A clinical management definition of
LTFU may be particularly useful in settings, such as
Malawi, where limited resources are available for tracing.
Indeed, high costs and a shortage of human resources
necessary for finding missing patients have contributed
to a backlog of patients needing to be traced in our set-
ting. Identifying patients earlier who are risk of becom-
ing lost and at risk of experiencing poor clinical
outcomes has implications for patient retention overall.
At the same time, if patients are prematurely classified
as lost, limited resources may be used to trace individ-
uals who ultimately will return on their own. Therefore,
a LTFU definition specific to clinical management can
inform clinicians of the optimum time to initiate the tra-
cing process (in real time) in such a way that both pa-
tient and health system outcomes are maximized.
Chi et al. developed an empirical approach to deter-
mining a best-estimate definition of LTFU [3]. In their
Zambian study, patients were classified as LTFU based
on the number of days they were late for their most re-
cent visit. They used weekly thresholds from ≥1 week to
≥26 weeks late. For each cut-off, they looked forward in
their dataset to determine the proportion of patients
who returned to care within the subsequent year. The
cut-off that minimized the misclassification of patients
as LTFU was considered the best-estimate definition, at
least based on the available data. Receiver operating
curves were plotted to demonstrate the cut-off that best
determined whether a patient returned to care within
the following year (i.e., the cut-off that minimized the
misclassification of patients as LTFU). One of the limita-
tions of this study however, was that only the patients’
last visit was included rather than all visits available [3]
and thus not all available data was utilized.
Importantly, clinical decisions in resource-constrained
settings are often made with incomplete and/or only
partial information [14]. An analytic method, therefore,
that is able to make use of all available data would be
ideal in order to obtain the most complete picture pos-
sible. At the same time, LTFU definitions for clinical
management purposes should be simple enough to cal-
culate and interpret so that they can be applied by clini-
cians and program planners with limited statistical
expertise and/or access to specific statistical software to
make decisions about patient tracing in real time.
A time to event analysis offers one such method to de-
termine the probability of a patient returning for a sub-
sequent visit based on how late they already are for an
expected visit. A time to event analysis studies the time
it takes for an outcome to occur, i.e., time to death, time
to disease [15, 16] or in this case time to a return. A
time to event analysis is often called a survival analysis
in the biostatistical literature. However, even when the
outcome of interest is not death, one can still use this
well-developed body of literature to study the time to
non-death events. Cumulative Distribution Functions
(CDFs), the complement of the survival function, are a
fundamental way to define random variables. Essentially,
they describe ‘Area Under the Curve’ functions [17, 18].
CDFs have been used and previously applied in multiple
epidemiologic studies including those related to spatial
analysis and environmental epidemiology [19–21], sur-
veillance and complex models of disease transmission
[22, 23], and studies involving clinical decision-making
[14, 24–27]. Related to the CDF is the hazard function,
which provides a measure of risk and plots the probabil-
ity of an event occurring at or over a period of time
given that the event has not already occurred [15, 28].
The hazard function in the present analysis provides
insight regarding the proportion of patients who return
each 1-week interval, of those who have yet to return.
As such, clinical staff can use this information to deter-
mine when tracing should be initiated (e.g., immediately
vs. waiting another week).
CDFs and hazard functions have numerous advan-
tages; for example, they represent data visually in a rela-
tively straightforward and intuitive manner [20]. They
can make use of all available data, and as a result tend to
present distributions as completely as the dataset allows
[15, 29, 30]. Since the CDF is 1 minus the survival func-
tion, the variance of the CDF is the same as that of the
survival function. This can be calculated through stand-
ard methods including Greenwood’s formula [31]. One
can refer to most standard books on statistical survival
analysis (e.g., Cox & Oakes, 1984) [32].
In the analysis reported here, the CDF and the hazard
function were both plotted and examined to determine
the probability that a patient would return each week,
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given that they had not yet returned, in order to identify
the LTFU cut-off that could best inform clinical manage-
ment and tracing procedures.
Methods
Dignitas International (DI), a Canadian non-governmental
organization, has worked in partnership with the Malawi
Ministry of Health (MOH) since 2004 to support delivery
of comprehensive HIV/AIDS care in the Zomba District,
one of the most densely populated districts in Malawi
(population: 670,500). District HIV prevalence is approxi-
mately 14.5 % although estimates within the district vary
by location and population group [33]. DI supported the
Malawi MOH to establish a tertiary referral HIV clinic at
Zomba Central Hospital in 2004, and since 2006 has also
supported the Zomba District Health Office to integrate
HIV-related services into existing primary health services
at decentralized health centres throughout the district
[34]. As per Malawian MOH guidelines, each patient who
starts ART is given a unique treatment unit ART registra-
tion number. This number is written on a paper-based pa-
tient card called a Master Card and put into the electronic
ART register for staff ’s use. All baseline registration data is
entered at the time of ART initiation. At each follow-up
(FU) visit, patient data is documented on the Master Card.
Following initiation, patients are asked to return 2 weeks
later and then monthly for the first 6 months. After
6 months, patients may be asked to return every 2–3
months depending primarily upon provider assessments
and drug availability [34, 35]. Patients are therefore given
a 2-week, 4-week, 8-week or 12-week supply of ART de-
pending on their expected frequency of visits. Data collec-
tion on MOH standardized registers and Master Cards are
completed by clinicians and health staff at baseline initi-
ation and at each subsequent FU visit.
For each follow-up visit, a ‘days late’ value was deter-
mined. The expected return date was calculated by using
the value for ART supply (in weeks) given at each FU visit.
A patient’s actual return date was compared to their ex-
pected return date. A patient was considered late if they
did not return at least 7 days after they were expected for
a FU visit. This definition is consistent with the 7-days late
value used to generate adherence proportions in the
Malawi treatment guidelines [35]. As well, discussion
with the clinical team in Zomba (personal communica-
tion Gabriel Mateyu and Dr. Kevin Bezanson, Dignitas
International, Zomba Malawi November 29, 2012) sup-
ported use of this definition of Late.
Building on the work of Chi et al. described above [3],
we sought to determine a clinical management LTFU cut-
off. Individuals 15 years of age and over who initiated
ART with Dignitas International (DI) supported sites in-
cluding the Central hospital and various health centres in
rural areas in Zomba, Malawi between 1 January 2007 and
1 July 2010 were eligible for inclusion. The analysis
was limited to all follow-up visits where the patient
was ≥1 week late. Similar to Chi et al., lateness was catego-
rized using 1-week cut-offs from ≥1 week to ≥26 weeks
late [3]. Therefore, this analysis was based on patients who
were at least ≥1 week late and likely to have run out of
ART, and thus at a high risk of becoming LTFU. Further,
patients were excluded if they were known to have trans-
ferred out, stopped ART or died, based on the limited suc-
cessful tracing completed [36]. Note we considered
including known deaths as a competing event although we
did not feel confident that we could accurately ascertain
deaths given incomplete tracing data. Furthermore, only
70 deaths ascertained through tracing were available for
this analyses and the median time from a last known visit
date and death ascertainment date (through tracing) was
299.5 days. As in Chi et al., we limited our analyses to pa-
tients who started ART and had a FU visit scheduled at
least 12 months prior to the end of the study period [3].
This helped to ensure that patients had adequate time to
return to the clinic [37]. Furthermore, given that the risk
of death is often highest in the first few months of treat-
ment [38–41], allowed us to minimize the inclusion of pa-
tients who did not return to the clinic because they had
died. As we could not ascertain deaths in our dataset, we
may have overestimated LTFU estimates.
The DI main dataset, available and maintained in Micro-
soft ACCESS, is composed of 21 separate tables. Several
queries were run in order to construct a single flat file
dataset that contained all relevant data (baseline and FU
visits) on patients meeting the inclusion criteria. Similar to
previous studies utilizing this method [42] the data was
presented over a wide range of cut-offs. At each 1-week
cut-off, the proportion of patients who returned for a sub-
sequent follow-up visit was identified along with 95 %
confidence intervals. The confidence intervals were con-
structed using the variance of the survival function. Plots
were generated in Microsoft Excel 2007 (See Additional
files 1 and 2). The data used in this study was extracted
from routine monitoring and evaluation data gathered as
part of the DI/Malawi MOH ART program in Zomba,
Malawi, using standardized national Master Cards and
registers. As all analyses were performed with de-
identified data that was extracted from routine program-
matic information, patients did not provide individual
written or verbal consent to participate in the study.
Ethical approval for data use was obtained from the Uni-
versity of Toronto HIV Research Ethics Board and the
National Health Sciences Research Committee in Malawi.
Results
In total, n = 4484 patients with n = 7316 follow-up visits
were included. The number of follow-up visits included
per patient ranged from 1 to 10 (Median: 1 visit). The
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median time on ART was 182 days (Interquartile
Range: 70–336 days). Included patients were receiving
care at n = 22 DI-supported sites. Approximately 40 %
of patients were receiving ART at the Central Hospital
(n = 1796) and 1929 (i.e., 43 %) were at least 9 weeks
late for a visit. The CDF demonstrated that the majority
of patients who were ≥1 week late and subsequently
returned to care did so within the first 4 weeks of a
missed visit, as per the initial sharp increase of the
curve (see Fig. 1).
Although fewer, patients who were ≥1 week late con-
tinued to return even after being 4 weeks late as demon-
strated by the more gradual increase in the curve until
approximately the 9-weeks-late cut-off. The curve then
begins to flatten out, suggesting that the proportion of
patients who returned for a subsequent visit decreased
once a patient was approximately 9 weeks late for a visit.
The hazard function (Fig. 2) shows two main spikes in
the proportion of patients who returned relative to those
who had yet to return, roughly at 4-week intervals, at
4 weeks and again around the 8-weeks-late cut-off. As in
the CDF, Fig. 2 demonstrates that after being at least
9 weeks late, the proportion of new patients who
returned relative to those who had yet to return de-
creased substantially.
Discussion
The clinical management LTFU definition of approxi-
mately 9 weeks identified in this study is relatively con-
sistent with previous literature on losses to follow-up
[3, 43, 44]. Chi et al. found that the use of an ≥8-
weeks-late cut-off minimized the misclassification of
patients as LTFU in their multi-site study in Zambia
[3]. The LTFU cut-off in this study is also similar to
what is currently used in Malawi to define patients who
are LTFU (i.e., 2 months late for a scheduled visit) and
this has implications for clinical management guide-
lines. At the time of the study (i.e., 2007–2010), the
Malawian MOH guidelines indicated that home visits
(following unsuccessful telephone call attempts) should
occur no later than 14 days or 2 weeks after a missed
visit [35]. In a parallel, exploratory analysis of Dignitas
tracing data, among the 83 patients who were success-
fully traced (of the 232 with available data), the median
number of days from the last visit to a successful trace
date was 181.5 days, ranging from 159 days to
306.5 days, considerably longer than the guidelines at
the time of this study [36]. Interestingly, the updated
2011 guidelines suggest that home visit attempts should
be made from 2 weeks after a missed visit [45]. This
subtle change in wording provides patients with more
time to return and can thus reduce unnecessary tra-
cing. Indeed, the functions presented indicate that most
patients who are already 1 week late and do eventually
return for a subsequent visit will return within the first
4 weeks of a missed visit. Currently, limited financial
and human resources available for tracing at Dignitas
ART sites has led to a backlog of patients waiting to be
traced. The findings presented here suggest that in
some cases, patients are being traced too prematurely
following a missed visit.
While our study identified a LTFU definition for clin-
ical management that made sense in our setting given
the data and frequency of visits, it is important to note
that the actual definition that we determined (i.e.,
9 weeks) may not be appropriate or relevant in other
programs and contexts [4]. Indeed, a universal definition
or a gold standard measure applied across programs
may not be appropriate given different program charac-
teristics [4]. The present study demonstrates LTFU
Fig. 1 Cumulative Distribution Function to Estimate a Lost To Follow-Up Cut-off
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questions can be reframed as a time to event analysis. By
reframing the question in this way and by using a well-
known, simple, robust, nonparametric technique from
this literature, we have found a strong and surprising re-
sult that has not, too our knowledge, been reported to
date. In the future, we hope to continue modifying tech-
niques from that literature in order to further under-
stand LTFU issues. This would include using methods
such as Cox proportional hazard models [46] or Poisson
regression methods for life table analysis [47, 48]. Our
goal was to introduce a simple methodology based on
survival functions that can be used to estimate evidence-
based cut-off for defining LTFU specific to clinical man-
agement. Investigators interested in examining factors
related to lost to follow-up could consider the vast the
well-developed literature and additional methods includ-
ing survival models, Cox proportional hazards models
and Poisson regression models. Furthermore, several
standardized definitions may be useful depending on the
population of interest [4, 11]. For example, a different
definition for pre-ART patients may be warranted given
different visit frequencies (e.g., no regular pharmacy
visits). As a result, a longer LTFU definition may be
more appropriate for pre-ART patients [12]. Definitions
of LTFU relevant for different population groups should
be explored further as they may have different cut-offs
that are appropriate.
There are several limitations of using CDFs and hazard
functions to establish clinical management LTFU cut-
offs. The primary issue relates to the judgement involved
in deciding which cut-off is meaningful for categorizing
LTFU for clinical management purposes given available
data. As noted above, different definitions of LTFU can
have a significant impact on LTFU estimates [2, 4].
While the shape of the functions provides some insight
(e.g., where the curve flattens in the CDF, spikes in the
hazard function), the weeks-late value used to define
LTFU in the present study is still a judgement made
without a formal set of criteria. The spikes, for example,
in the hazard function may be reflective of the expected
frequency of visits and the ART supply given (e.g., 4 or
8 week supply). It is worth noting, however, that the vis-
ual appraisal of both functions suggests a ≥9-weeks-late
clinical management LTFU cut-off. This method there-
fore has strength in that it can act as a tool for triaging
[37] patients for active tracing.
As in other methods, data preparation is a necessary
step to ensure that the curves can be generated (See
Additional file 1). To establish whether a patient was late
for a visit, the ART supply given (in weeks) at their most
recent visit was used to determine when they would be
expected for their next visit. This information may not
always be available given the lack of tracking data and,
therefore, the date of the next scheduled visit may also
not be reported. Interestingly, 98 % of ART clinics in
one East African multi-site study did report recording
the next expected appointment date, although under a
third actually compared the expected appointment date
with the actual return date [1].
Missing data is often a challenge in clinical databases.
Generally, patients are said to be censored when infor-
mation on time to event (of interest) is not available for
all participants, including those whom become LTFU
[49]. As a result, LTFU is often considered a non-
informative censoring event in cohort analyses [2, 50].
In this program of research, however, LTFU is the
Fig. 2 Hazard Function to Estimate a Lost to Follow-Up Cut-off
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primary outcome of interest. The reasons for censoring
the examined data therefore, are mostly not available, as
incomplete follow-up occurs for many patients without
adequate resources to enable full or complete follow-up.
While death is a competing risk for becoming LTFU
(i.e., patients who die are no longer at risk for becoming
lost), given incomplete data on known deaths (primarily
due to poor ascertainment through tracing) for individ-
uals who had missed their visits, we did not explore
death as a competing risk in the present analysis. This is
an important limitation as this can lead to overestima-
tions of LTFU [51] even those used for clinical manage-
ment purposes. Death reporting is neither compulsory
nor enforced legally in Malawi [52]. As a result, deaths
are generally under reported; this makes linkages with
health surveillance and clinical tracking data challenging.
However, it is worth noting that while some of those lost
to follow-up probably died (about one-third of those
successfully traced in this program) effectively taking
them out of the denominator of those ‘at risk’ of return-
ing for an additional follow-up visit. However, even if
20 % of those LTFU (larger than the 17 % in Malawi
overall) are removed from the denominator i.e. censored,
they are unlikely to affect the fundamental shape of the
curves substantially, as per the stratified analyses. In-
deed, numerous studies have demonstrated higher rates
of mortality in the first few months after ART initiation
[38–41]. However, while we could not fully account for
the impact of deaths in this study, we sought to
minimize the number of patients who died in this data-
set by excluding patients who had not initiated ART at
least 12 months prior to the end of the study although it
is important to note that each patient in this study had
at least 12 months to return to FU visit as in Chi et al.
[12]. As we did not have a specific time limit that pa-
tients had to return by in order to be defined as clinic-
ally LTFU, there are variable times to return. For
example, a patient with a scheduled follow-up visit early
in the study period of interest has a longer opportunity
to return versus a patients who scheduled FU visit was
approximately 12 months from study endpoint (i.e., June
30 2009). Furthermore, a patient may still return after
the study period and therefore only have experienced a
gap in care rather than be truly LTFU. As visit-level data
(versus patient-level) was used to establish clinical man-
agement LTFU cut-offs, there may be a differential con-
tribution to data from different patients, as they may
have different numbers of follow-up visits included.
While it is worth noting that the median number of
follow-up visits was 1, the number of follow-up visits
ranged from 1 to 10. The small number of follow-up
visits per patient may stem from our inclusion criteria of
being at least 7 days late for an expected follow-up visit.
In a previous analysis [53], we noted that a patient
returns to the clinic within 6 days of an expected follow-
up visit and are only 7 days late in approximately 17 %
of follow-up visits. This may partially explain why the
median number of follow-up visits per patient was 1. Re-
gardless, we did not account for multiple follow-up visits
per patient in the present study as we were focusing on
clinician’s decision about a particular follow-up visit.
CDFs provided a comprehensive presentation of data
over a large range of cut-offs and offered guidance re-
garding the clinical management LTFU cut-off in this
setting. The cut-off was further corroborated through
the plotting of the associated hazard function. Import-
antly, there is no gold standard definition of retention
and our clinical management LTFU definition may not
be appropriate in other settings given that program char-
acteristics and populations of interests can widely across
programs and settings [4]. However, having a sense of
the proportion of patients who return weekly can help
clinical staff, regardless of the program or setting, to pre-
dict the number of patients to be expected each week.
For example, at the 3 weeks late cut-off, it is expected
that approximately 40 % of the remaining patients who
are late and who will return will show up during the fol-
lowing week. Clinical staff can then decide the value in
waiting another week to start tracing versus implement-
ing tracing immediately.
Conclusions
Flexible and informative, the simple functions plotted here
did not require advanced statistical expertise and were cre-
ated using Microsoft Excel, making it a particularly prac-
tical method for HIV programs in resource-constrained
settings. As a result, they should be considered additional
tools for ART program monitoring specialists and clinical
managers in Malawi and other resource-constrained set-
tings. In addition to identifying other clinical management
definitions that may be relevant for different population
groups (e.g., pre-ART patients), future studies should pilot
the use of survival functions and explore the acceptability
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